Scott Tyler Aaronson
Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt; Adjunct Professor of Psychiatry, University of Maryland School of Medicine
Data updated
Research Footprint
Scott Tyler Aaronson appears in 8 tracked papers (2022–2026), most studied alongside Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Guy Goodwin, Robin Carhart-Harris and Allan Young.
Background & Research
Scott T. Aaronson, MD, is a psychiatrist specializing in treatment-resistant affective disorders and psychedelic-assisted treatment research. He serves as Chief Science Officer of the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt and is an Adjunct Professor of Psychiatry at the University of Maryland School of Medicine. His work has focused on novel interventions for severe depression, including psilocybin and neurostimulation.
Key Impact
He is a leading psychiatrist in treatment-resistant depression and a key investigator on psilocybin studies, including work on preparation, dosing, outcomes, and mechanisms of psychedelic-assisted therapy.
Collaboration Network
30 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Scott Tyler Aaronson is associated with.
Sheppard Pratt Health System
Sheppard Pratt Health System is a leading non-profit psychiatric hospital and health system in Towson, Maryland, home to the Center of Excellence for Psilocybin Research and Treatment — the first international center of its kind — established in partnership with COMPASS Pathways; it has conducted landmark psilocybin trials including the first trial for bipolar type II depression (published in JAMA Psychiatry with 80% remission at 12 weeks), psilocybin for treatment-resistant depression (published in NEJM), and psilocybin for TRD with chronic suicidal ideation.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →